Statin Eligibility Prior to Myocardial InfarCtion

Myocardial Infarction Clinical Trial

— StatinEPIC  

Official title:

Statin Eligibility Prior to Myocardial InfarCtion in Jordanians

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03485742
• Other study ID #: JCCStatinEpic2018
• Status: Terminated
• Start date: April 22, 2019
• Est. completion date: June 10, 2019

Study information

• Verified date: June 2019
• Source: Jordan Collaborating Cardiology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study (Statin Eligibility Prior to myocardial infarction (MI) in Jordanians, StatinEPIC) is

1. Cross sectional

2. Non interventional

3. One encounter per patient. No follow up. It addresses a major issue of primary prevention in Jordanians especially the young population, namely the issue of lipid lowering agents before sustaining an acute MI. A recent study in USA showed that 50% of patients who sustained MI were not eligible to statins had they been evaluated before the heart attack. It is largely unknown if a larger percentage of Middle Eastern patients who sustain a heart attack would be eligible to receive lipid lowering agents.

4. The PI will overlook the whole process. Dr Ahmad Tamari, the assistant to the PI will asses this whole process of data collection, management and manuscript drafting.

Description:

Statins, when use as primary cardiovascular prevention strategy, have been shown to lower future acute cardiovascular events, especially myocardial infarction. However the use of statins in this context (i.e., primary prevention) is governed by guidelines that limit the use of statins to four high risk populations: (1) hose with known cardiovascular disease, (2) those with low-density lipoprotein cholesterol (LDL-C) levels 190 mg/dl or above, (3) diabetics with LDL-C levels 70-189 mg/dl, and (4) those with an estimated 10-year atherosclerotic cardiovascular disease risk score of 7.5% or more.

Unfortunately, some individuals are still at risk of sustaining MI despite the fact that they do not fit into one of these four high risk groups eligible for statins.

StainEPIC will enroll consecutive patients admitted with MI who are not on statins to examine their eligibility for these medications based on the AHA/ACC guidelines.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 740
• Est. completion date: June 10, 2019
• Est. primary completion date: June 10, 2019
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Adults admitted with MI, age 30 to 75

• known lipid profile

Exclusion Criteria:

• on statin before enrollment

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Statins

Intervention

Other:
• No intervention
No intervention. Collection of data on statin eligibility in patients admitted with MI

Locations

Country	Name	City	State
Jordan	Istishari Hospital	Amman
Jordan	Jordan Hospital	Amman
Jordan	Khalidi Hospital & Medical Center	Amman
Jordan	The University of Jordan	Amman
Jordan	King Abdullah University Hospital	Irbid

Sponsors (1)

Lead Sponsor	Collaborator
Jordan Collaborating Cardiology Group

Country where clinical trial is conducted

Jordan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Eligible patients for statin therapy	The primary outcome is to calculate the percentage of enrolled patients who do meet the AHA/ACC Guidelines for receiving statins as a primary prevention measure.	Within 24 hour of enrollment